LIFE
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
Ethos Technologies Inc. (LIFE) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Financial Services sector peers. Its strongest pillar is Growth (B); its weakest is Revisions (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B- (3.1) | B (3.4) | C+ (2.8) | B (3.3) | F (0.0) | C+ (2.5) |
| 2026-11-06 | B- (3.1) | B+ (3.7) | C+ (2.8) | B (3.2) | F (0.0) | C+ (2.6) |
| 2026-10-30 | B- (2.9) | A- (4.0) | B- (2.9) | A+ (5.0) | F (0.0) | B- (3.0) |
| 2026-10-23 | B- (2.9) | A- (4.0) | B- (2.9) | A+ (5.0) | F (0.0) | B- (3.0) |
| 2026-10-16 | B- (3.0) | A- (4.0) | B- (2.9) | A+ (5.0) | F (0.0) | B- (3.0) |